医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection
lear has filed an Amended Answer in response to the U.S. Government’s lawsuit against the company. According to Nathan Jones, Xlear’s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of protection in fighting COVID-19, that our public health officials are ignoring; Second, it lays out in greater detail how the U.S. Government’s lawsuit is an effort to censor science that doesn’t comport with the Government’s vaccine-myopic, failing strategy to combat the disease; Third, it documents how experts, including Dr. Fauci, are increasingly saying the nose is the critical place to fight the virus.… 続きを読む
2022年08月16日 AM02:42
2022年08月15日
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
piAxis Therapeutics, a leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a collaboration to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.… 続きを読む
2022年08月15日
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
eiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today announced a strategic agreement with Ontada®, a McKesson business with leading provider technology and actionable real-world research, education, and evidence in oncology, to improve U.S. community oncology care through the development of real-world evidence (RWE) data, tools, and insights to help increase access to affordable, cutting-edge therapies.… 続きを読む
2022年08月15日
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
ositive topline results from the DESTINY-Breast02 phase 3 trial of ENHERTU® (trastuzumab deruxtecan) versus physician’s choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1). The trial also met the key secondary endpoint of improved overall survival.… 続きを読む
2022年08月13日
Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
n arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and will continue to develop and commercialize these medicines as planned.… 続きを読む